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Results: Of 939/1077 (87%) HPV tested OPC, LDH level was 
available in 611/678 (90%) HPV+ and 225/261 (86%) HPV–. Median 
follow up was 4.4 and 4.1 years for the HPV+ and HPV– cohorts, 
respectively. Among HPV+, LDH E (n = 223) versus NE (n = 388) 
cases comprised older age (median 60 versus 58 years, p = 0.02) 
and slightly larger primary tumour volume (GTV) (median 24 
versus 21 cc, p = 0.08) but similar T (p = 0.27) and N-category 
(p=0.34), smoking pack-years (sPY) (p = 0.27), and alcohol 
consumption (p = 0.25). A lower three-year OS (79% versus 87%, 
p < 0.01) and RFS (79% versus 89%, p  < 0.01) were found in HPV+ 
LDH E versus NE. MVA for HPV+ patients confirmed that LDH-E 
increased risk of death [HR 1.5 (1.1-2.2), p = 0.03] and relapse 
[HR 1.8 (1.2-2.7), p < 0.01) after adjusting for sPY (OS: p < 0.01; 
RFS: p = 0.94), age (OS: p = 0.09; RFS: p = 0.63), T3-4 (OS: p = 
0.02; RFS: p = 0.48), N2c-3 (OS: p = 0.08; RFS: p < 0.01), GTV-1° 
(OS: p < 0.01; RFS: p < 0.01) and chemotherapy (OS: p < 0.01; 
RFS: p = 0.02). The prognostic significance of LDH-E was 
confirmed by MVA within the subset of HPV+ patients with normal 
liver function [OS: HR 1.7 (1.1-2.7), p = 0.01; RFS: 2.0 (1.3-3.3), 
p < 0.01]. RPA divided HPV+ OPC into low-risk (T1-3N0-N2c_LDH-
NE) and high-risk (T4 or N3 or T1-3N0-N2c_LDH-E) subgroups. The 
three-year OS was 91% versus 72% and RFS was 91% versus 75%, 
respectively (both p < 0.01). In the HPV– cohort, no differences 
were found in baseline characteristics or outcomes between LDH 
E (n = 86) and NE (n = 139) cases (three-year OS: 59% versus 52%, 
p = 0.96; RFS: 68% versus 68%, p = 0.91), and the non-prognostic 
effect was confirmed by MVA (OS: HR 1.2, p = 0.43; RFS: HR 1.1, 
p = 0.54) 
Conclusions: This study shows that pre-RT serum LDH elevation 
is prognostic for HPV+ OPC independent of liver function but non-
prognostic for HPV– patients. LDH has the potential to be 
included in HPV+ prognostic groupings, similar to other tumours. 
T1-3N0-N2c HPV+ OPC with elevated LDH appears associated 
with increased risk of death and disease relapse comparable to 
T4 or N3 subsets 
100 
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Purpose: Breast-conserving surgery followed by adjuvant 
radiation therapy (RT) is the standard treatment for early-stage 
breast cancer (EBC). Up to 30% of patients experienced moist 
desquamation or ≥ Grade 2 skin toxicity following standard 
fractionation tangent field 3D-conformal radiotherapy (3D-CRT). 
The feasibility of skin-sparing helical tomotherapy (SSHT) by 
configuring skin as an organ at risk (OAR) was established in an 
earlier dosimetric study. The aim of this study was to assess 
whether SSHT would reduce the incidence of ≥Grade 3 acute skin 
toxicity in EBC patients undergoing RT. 
Methods and Materials: This single institution Phase III 
randomized control trial comparing SSHT to 3D-CRT for RT in EBC 
patients with acute skin toxicity as the primary endpoint. The 
skin as OAR was defined as a 5 mm strip of ipsilateral breast skin 
and we employed a constraint on the skin volume receiving dose 
up to 40 Gy while delivering dynamic IMRT as described earlier. 
Patients were assessed weekly during RT and then at six and 12 
weeks post-RT. Acute toxicity parameters recorded were level of 
skin erythema, radiation dermatitis, and pain. 
Results: During the period of May 2008 to January 2012, 177 EBC 
patients were enrolled into the study and 90 were randomized to 
3D-CRT arm and 87 to SSHT. The mean age was 59 years. SSHT 
achieved more homogenous coverage of the target than 3D-CRT. 
HT arm had lower proportion of acute toxicity. The incidence of 
erythema and moist desquamation were significantly higher in 
the 3D-CRT arm than in the SSHT treated arm (erythema: 60% 
versus 39%; p = 0.005; moist desquamation: 33% versus 11%; 
P=0.0003). No patients in the SSHT arm had exudate while 11% 
of patients in the 3D-CRT arm did (0% versus 11%; p = 0.0014). 
Patients in the 3D-CRT arm had increased incidence of ≥ Grade 3 
tenderness and discomfort of breast (tenderness: 54% versus 24%; 
p < 0.0001, discomfort: 9% versus 1%; p = 0.019), but ≥ Grade 3 
itching, burning and pulling were not significantly different 
between the treatment arms. The independent prognostic 
factors that contributed significantly to acute toxicity in the 
multivariate analysis were large breast volume, adjuvant 
chemotherapy, and 3D-CRT. 
Conclusions: SSHT significantly reduced the incidence of moist 
desquamation compared with 3D-CRT. Incidence of acute 
toxicity was correlated with large breast volume, adjuvant 
chemotherapy, and 3D-CRT. Combining an IMRT approach with 
explicit reduction in skin dose may further improve both acute 
and late skin toxicity for patients undergoing adjuvant breast 
radiotherapy.  
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Purpose:  SBRT is an effective treatment that delivers highly 
conformal doses of radiation to target volumes, sparing normal 
organs. Despite the advancements in this technique for other 
disease sites, its role in gynecological cancers remains unclear. 
This systematic review aims to evaluate toxicity and outcomes 
of SBRT in gynecological malignancies. 
Methods and Materials: In accordance to PRISMA guidelines, 
a systematic review of the literature was conducted on 
studies reporting SBRT in gynecological malignancies. EMBASE, 
MEDLINE and Cochrane databases were systematically 
searched for relevant studies until October 2015. All 
relevant studies evaluating the role of local-regional SBRT 
for gynecological malignancies (excluding CNS, extra-pelvic 
and extra-para-aortic lesions) were included. Relevant data 
regarding toxicities and outcomes were abstracted and 
analyzed. 
Results: From 534 references, 23 articles from 2004 to 2015 were 
selected, comprising a total of 382 patients. Studies were 
classified into six categories: 1) Radical treatment with SBRT as 
local boost for cervix tumours: total of 34 patients were 
identified in seven studies. Treated PTV median volume (MV) 
ranged from 41 to 146 mL and local control (LC) from 0 to 100% 
in a median follow up time of 4 to 22 months. Gastro-intestinal 
(GI) G3/4 toxicity was ~12%. 2) Radical treatment with SBRT as 
a local boost for endometrial cancer: 13 patients found in three 
studies. Eighty-five percent of the patients were from one series 
reporting a 55% LC at 18 months. G3 GI toxicity was reported in 
one out of 13 patients. 3) SBRT to lymph node metastases: 197 
patients were found in seven studies. Treated PTV-MV ranged 
from 16 to 42 mL and LC 60-100% in a range of median follow up 
time of 14-20 months. Long-term G3/4 GI and genito-urinary 
(GU) toxicity was 3% and 0.005%, respectively. 4) Pelvic 
recurrences treated with SBRT: Majority received a course of 
radiotherapy before, either as a previous treatment or as first 
course on salvage attempt. Seventy-two patients were found in 
10 studies. Treated PTV-MV ranged from 20 to 154 mL and LC 
from 51% to 100% in a median follow up range of 4-22 months. 
Chronic G3/4 GI and GU toxicity were 22% and 1.5%, respectively. 
5) Adjuvant treatment with SBRT to the vaginal vault after EBRT:
61 patients were found in three studies. LC was 91-92% (1-11 
years) and GI G3 toxicity was 3%. 6) Two studies included two 
